ORION PHARMA (UK) LIMITED

What ORION PHARMA (UK) LIMITED does

Orion Pharma (UK) Limited is the UK sales and marketing subsidiary of Orion Corporation, a Finnish pharmaceutical group founded in 1917 and listed on Nasdaq Helsinki. The UK entity operates from Reading, Berkshire, with 11-50 employees focused on marketing Orion's pharmaceutical portfolio to UK healthcare professionals, pharmacies and healthcare organisations, including compliance with ABPI disclosure requirements for HCP and HCO payments. It is one of three R&D centres operated by the parent group alongside Finland and the United States, providing the UK a dual sales-and-research footprint.

The company's core products span multiple therapy areas: oncology (with a focus on hormone-mediated cancers such as prostate), pain management (including non-addictive treatments for nerve damage and musculoskeletal pain), respiratory diseases via the proprietary Easyhaler dry powder inhaler platform, neurological diseases led by Parkinson's medicines used globally for over 40 years, women's health through hormone replacement therapies with more than 7 million patient years of accumulated use, and self-care products including emollient creams, vitamins, nutritional supplements and CE-marked medical devices. The group operates six production sites in Finland and serves over 100 countries.

The business model is sales-led, marketing human pharmaceuticals, veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) primarily through direct engagement with healthcare professionals and distribution via UK pharmacies. Pricing is regulated and not publicly disclosed. Revenue is generated through product sales rather than subscription or licensing models at the UK entity level, with intra-group flows from the Finnish parent representing the principal commercial dependency. The company collaborates with global research institutes and patient organisations, and discloses payments to UK HCPs and HCOs under ABPI transparency rules.

Name

ORION PHARMA (UK) LIMITED

Legal name

Orion Pharma (UK) Limited

Website

https://orionpharma.co.uk

Company type

Private

Founded year

1917

Operating status

Operating

Headcount range

11–50 employees

Short description

Orion Pharma (UK) Limited is the UK sales and marketing subsidiary of Finnish pharmaceutical group Orion Corporation, marketing prescription and self-care pharmaceuticals across oncology, pain, respiratory, neurology and women's health to UK healthcare professionals and pharmacies.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Inhalers (MDI/DPI/SMI) (HLAHAIAI), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Human pharmaceuticals
• Respiratory inhalers
• Oncology therapeutics
• Pain management drugs
• Active pharmaceutical ingredients

Headquarters

HQ city

Reading, Berkshire

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Human Pharmaceuticals: Development, manufacture and marketing of human pharmaceutical products including prescription medicines and self-care products across therapy areas including oncology, pain management, respiratory diseases, neurological diseases, and women's health.
2. Veterinary Pharmaceuticals: Development, manufacture and marketing of veterinary pharmaceutical products.
3. Active Pharmaceutical Ingredients: Manufacturing and marketing of active pharmaceutical ingredients (APIs) for use in pharmaceutical formulations.
4. Self-care Products: Sale of self-care products including emollient creams, vitamins, nutritional supplements, CE-marked medical devices, and daily well-being products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Orion Pharma (UK) Limited develops, manufactures, and markets human pharmaceuticals (oncology, pain management, respiratory, neurological, and women's health therapy areas), veterinary pharmaceuticals, active pharmaceutical ingredients, and self-care products for the UK market. Its flagship proprietary drug delivery technology is the carbon-neutral Easyhaler dry powder inhaler used in respiratory care, alongside a hormone replacement therapy portfolio with more than 7 million patient years of use and over 40 years of Parkinson's disease medicine heritage.

Product overview

Orion Pharma (UK) Ltd is the UK subsidiary of Orion Corporation, a globally operating Finnish pharmaceutical company founded in 1917. The company develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The product portfolio is organized around several core offerings: Easyhaler dry powder inhalers (carbon neutral) for respiratory diseases such as asthma and COPD; hormone replacement therapies (HRTs) for women's health and menopause management with over 7 million patient years of use; and self-care products including emollient creams, vitamins, nutritional supplements and medical devices. The company's pharmaceutical R&D focuses on core therapy areas of oncology (particularly hormone-mediated cancers like prostate cancer) and pain management (including treatments for nerve damage and musculoskeletal pain). Orion also develops veterinary drugs and generic pharmaceuticals. Products are available in over 100 countries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Easyhaler Proprietary dry powder inhaler device for the treatment of respiratory diseases such as asthma and COPD; the Easyhaler product line is entirely carbon neutral and is prescribed to patients in the UK and over 100 countries worldwide.
• Hormone Replacement Therapies (HRT) Hormone replacement therapy products developed to help women manage menopausal symptoms including hot flushes, mood swings, night sweating, vaginal dryness, and reduced sex drive, with more than 7 million patient years of clinical use.
• Self-care Products Range of consumer health products including emollient creams, vitamins, nutritional supplements, CE-marked medical devices, and other daily health and well-being items marketed through UK pharmacies.
• Human Pharmaceuticals Prescription pharmaceuticals for human use covering therapy areas including pain management, oncology (notably hormone-mediated cancers such as prostate cancer), respiratory diseases, neurological diseases (Parkinson's), and women's health.
• Veterinary Pharmaceuticals Pharmaceutical products developed, manufactured, and marketed for veterinary use across animal health indications.
• Active Pharmaceutical Ingredients (APIs) Active pharmaceutical ingredients manufactured at Orion's six Finland-based production sites for use in pharmaceutical formulations supplied globally.

Named customers4 records

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Patient OrganisationsminorOthersOrion supports charities and patient organisations through the Orion Support Programme and Orion Donations & Grants by year. Funding and support is disclosed annually.

Scale indicators7 records

Expansion highlights5 records

Direct peers

• AstraZeneca: UK-headquartered global pharma with a major respiratory franchise (Symbicort DPI, Breztri, Fasenra) plus oncology and women's health adjacencies, making it the closest direct competitor to Orion Pharma's UK respiratory and specialty pharma footprint.
• Chiesi Farmaceutici: Italian privately-owned respiratory specialist (NEXThaler DPI, Foster) competing head-to-head with Easyhaler in DPI devices, with similar therapy-area focus on asthma and COPD.
• Teva Pharmaceutical Industries: Global pharma with significant respiratory franchise (ProAir, AirDuo, ArmonAir) plus large generics and specialty businesses, mirroring Orion's mix of branded respiratory, generics and APIs.
• GSK: Global pharma with the largest inhaler franchise (Advair/Diskus, Trelegy Ellipta) and a UK base; directly comparable on respiratory device technology, UK commercial footprint, and broad pharma R&D scale.
• Boehringer Ingelheim: Privately-held global pharma with major respiratory franchise (Spiriva Respimat) plus neurology and cardiometabolic adjacencies, comparable in therapy-area breadth and respiratory device focus.

Broad incumbents

• Novartis: Swiss global pharma with Sandoz generics, broad specialty pharma pipeline and neurology assets; comparable as a broad-based competitor with overlapping therapy-area and generic exposure.
• Bayer: German global pharma with broad prescription and consumer health portfolio, comparable in women's health, cardiovascular and specialty pharma adjacencies to Orion's diversified therapy mix.
• Merck KGaA: German global healthcare company with pharma (especially neurology and oncology) plus life sciences operations; comparable as a diversified European pharma with overlapping therapy areas.

Emerging players

• Vectura Group: DPI device technology specialist (now part of Philip Morris), enabling third-party inhaled therapeutics; directly comparable on inhaler platform technology that underpins Easyhaler.

Regional players

• Hikma Pharmaceuticals: UK- and MENA-headquartered specialty pharma and generics company with similar therapy-area breadth, comparable mid-cap UK-listed pharma model and overlapping respiratory, women's health and pain categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/orion-pharma-uk-limited

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ORION PHARMA (UK) LIMITED